UNIGE document Scientific Article - Meta-analysis
previous document  unige:20810  next document
add to browser collection
Title

Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years

Authors
Bruyere, O.
Collette, J.
Decock, C.
Ortolani, S.
Cormier, C.
Detilleux, J.
Reginster, J-Y
Published in Osteoporosis International. 2010, vol. 21, no. 6, p. 1031-1036
Abstract SUMMARY: From two randomised controlled trials, it is shown that 3-month changes in biochemical markers of bone formation (bone-specific alkaline phosphatase and C-terminal propeptide of type I procollagen) were associated with 3-year bone mineral density (BMD) changes, but not fracture incidence in patients treated with strontium ranelate. INTRODUCTION: The purpose of this study was to assess if short-term change in biochemical markers of bone remodelling is associated with long-term BMD change and fracture incidence observed during treatment with strontium ranelate. METHODS: From the SOTI and TROPOS trials, bone-specific alkaline phosphatase (BALP), C-terminal propeptide of type I procollagen (PICP), serum C-terminal telopeptides (S-CTX) and urine N-terminal telopeptides of type I collagen (U-NTX) were assessed at baseline and after 3 months. RESULTS: Two thousand three hundred seventy-three women were included in this study. Multiple regression analysis showed that 3-month changes in PICP and BALP but not s-CTX I nor s-NTX I were significantly (p < 0.001) associated with 3-year BMD changes at the lumbar spine and the femoral neck. Changes in s-CTX I, PICP and BALP were significantly associated with change in total proximal femur BMD. Changes in biochemical markers explain less than 8% of the BMD changes. The 3-month changes in BALP, PICP s-CTX I and s-NTX I were not significantly associated with fracture incidence. CONCLUSIONS: Short-term changes in biochemical markers of bone formation are associated with future BMD changes in patients treated with strontium ranelate, suggesting a bone-forming activity of this treatment, but are not appropriate to monitor the efficacy of strontium ranelate at the individual level.
Keywords AgedAged, 80 and overAlkaline Phosphatase/bloodBiological Markers/bloodBone Density/*drug effects/physiologyBone Density Conservation Agents/pharmacology/*therapeutic useBone Remodeling/*drug effects/physiologyFemaleFemur Neck/physiopathologyFollow-Up StudiesHumansLumbar Vertebrae/physiopathologyMiddle AgedOrganometallic Compounds/pharmacology/*therapeutic useOsteoporosis, Postmenopausal/complications/drug therapy/physiopathologyOsteoporotic Fractures/etiology/physiopathology/*prevention & controlPeptide Fragments/bloodProcollagen/bloodRandomized Controlled Trials as TopicSpinal Fractures/etiology/physiopathology/prevention & controlThiophenes/pharmacology/*therapeutic use
Identifiers
PMID: 19813043
Full text
Structures
Research group Nutrition et os (66)
Citation
(ISO format)
BRUYERE, O. et al. Relationship between 3-month changes in biochemical markers of bone remodelling and changes in bone mineral density and fracture incidence in patients treated with strontium ranelate for 3 years. In: Osteoporosis International, 2010, vol. 21, n° 6, p. 1031-1036. https://archive-ouverte.unige.ch/unige:20810

164 hits

0 download

Update

Deposited on : 2012-05-23

Export document
Format :
Citation style :